Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow myopia progression in children and adolescents; BRIMOCHOL PF and Carbachol PF pupil-modulating eye drops to correct for the loss of near vision associated with presbyopia; TAB014, a clinical-stage bevacizumab-based antibody indicated for wAMD; and PAN-90806 a drug indicated in the treatment of wAMD and DME. In addition, the company develops ZK002, a protein with a novel mechanism of action to contain inflammation and vascular flood leakage; Bimatoprost, a generic drug used in the treatment of glaucoma; Levobetaxolol HCl, a generic eye drop used in the treatment of glaucoma to lower pressure in the eye; and Travoprost, a prescribed PGAs for open-angle glaucoma. Further, it is involved in the development of Bimatoprost Timolol for targeting glaucoma; Latanoprost Timolol, a PGA and ß blocker combination eye drop targeting glaucoma; Travoprost Timolol, a potential first-to-market generic travoprost timolol; and Latanoprost, a prescribed PGAs for open-angle glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.